PMID- 17948929
OWN - NLM
STAT- MEDLINE
DCOM- 20071129
LR  - 20220227
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 13
IP  - 42
DP  - 2007 Nov 14
TI  - Novel genetic markers in inflammatory bowel disease.
PG  - 5560-70
AB  - Genetic factors play a significant role in determining inflammatory bowel disease 
      (IBD) susceptibility. Epidemiologic data support genetic contribution to the 
      pathogenesis of IBD, which include familial aggregation, twin studies, racial and 
      ethnic differences in disease prevalence. Linkage studies have identified several 
      susceptibility genes contained in different genomic regions named IBD1 to IBD9. 
      Nucleotide oligomerization domain (NOD2) and human leukocyte antigen (HLA) genes 
      are the most extensively studied genetic regions (IBD1 and IBD3 respectively) in 
      IBD. Mutations of the NOD2 gene are associated with Crohn's disease (CD) and 
      several HLA genes are associated with ulcerative colitis (UC) and CD. Toll like 
      receptors (TLRs) have an important role in the innate immune response against 
      infections by mediating recognition of pathogen-associated microbial patterns. 
      Studying single-nucleotide polymorphisms (SNPs) in molecules involved in 
      bacterial recognition seems to be essential to define genetic backgrounds at risk 
      of IBD. Recently, numerous new genes have been identified to be involved in the 
      genetic susceptibility to IBD: NOD1/Caspase-activation recruitment domains 4 
      (CARD4), Chemokine ligand 20 (CCL20), IL-11, and IL-18 among others. The 
      characterization of these novel genes potentially will lead to the identification 
      of therapeutic agents and clinical assessment of phenotype and prognosis in 
      patients with IBD.
FAU - Rodriguez-Bores, Lorena
AU  - Rodriguez-Bores L
AD  - Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Vasco de Quiroga 15 colonia Seccion XVI, Tlalpan, CP 
      14000, Mexico.
FAU - Fonseca, Gabriela-C
AU  - Fonseca GC
FAU - Villeda, Marco-A
AU  - Villeda MA
FAU - Yamamoto-Furusho, Jesus-K
AU  - Yamamoto-Furusho JK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Genetic Markers)
RN  - 0 (IL25 protein, human)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-23)
RN  - 0 (NOD2 protein, human)
RN  - 0 (Nod2 Signaling Adaptor Protein)
RN  - 0 (Receptors, Calcitriol)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Chromosome Mapping
MH  - Genetic Markers
MH  - Humans
MH  - Immunity, Innate
MH  - Inflammatory Bowel Diseases/*genetics
MH  - Interferon-gamma/genetics
MH  - Interleukin-17/genetics
MH  - Interleukin-23/genetics
MH  - Major Histocompatibility Complex
MH  - Nod2 Signaling Adaptor Protein/genetics
MH  - Receptors, Calcitriol/genetics
PMC - PMC4172734
EDAT- 2007/10/24 09:00
MHDA- 2007/12/06 09:00
PMCR- 2007/11/14
CRDT- 2007/10/24 09:00
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
PHST- 2007/11/14 00:00 [pmc-release]
AID - 10.3748/wjg.v13.i42.5560 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2007 Nov 14;13(42):5560-70. doi: 10.3748/wjg.v13.i42.5560.